Avet Pharmaceut Patent-Cliff Exposure & CMS Drug Spending Portfolio

Avet Pharmaceut (US): 2 reconciled FDA prescription therapies, $414K 2024 CMS Part D & Medicaid spend, and $1,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$414K
2024 Medicare Part D Spend$165K
2024 Medicaid Spend$249K
California HCAI SB 17 FilingsSpecialty launch notice ($1,500 intro WAC)